Sugammadex
- TRADE NAME: Bridion (Organon)
- INDICATIONS: Reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
- CLASS: Cyclodextrin, Selective relaxant binding agent
- HALF-LIFE: ~2 hours
FDA APPROVAL DATE: 12/15/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
No data available
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sugammadex in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric